Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueDepreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - Net
Ratios

Insight Molecular Diagnostics (IMDX) Accumulated Depreciation & Amortization (2020 - 2023)

Insight Molecular Diagnostics' Accumulated Depreciation & Amortization history spans 4 years, with the latest figure at $404000.0 for Q3 2023.

  • For Q3 2023, Accumulated Depreciation & Amortization fell 63.27% year-over-year to $404000.0; the TTM value through Sep 2023 reached $404000.0, down 63.27%, while the annual FY2022 figure was $1.5 million, 87.5% up from the prior year.
  • Accumulated Depreciation & Amortization for Q3 2023 was $404000.0 at Insight Molecular Diagnostics, down from $435000.0 in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $1.5 million in Q4 2022 and bottomed at -$4.2 million in Q3 2020.
  • The 4-year median for Accumulated Depreciation & Amortization is $419500.0 (2023), against an average of $203642.9.
  • The largest annual shift saw Accumulated Depreciation & Amortization soared 155.59% in 2021 before it tumbled 63.27% in 2023.
  • A 4-year view of Accumulated Depreciation & Amortization shows it stood at $313000.0 in 2020, then skyrocketed by 155.59% to $800000.0 in 2021, then skyrocketed by 87.5% to $1.5 million in 2022, then plummeted by 73.07% to $404000.0 in 2023.
  • Per Business Quant, the three most recent readings for IMDX's Accumulated Depreciation & Amortization are $404000.0 (Q3 2023), $435000.0 (Q2 2023), and $450000.0 (Q1 2023).